{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-134854","form_type":"8-K","ticker":"KOD","cik":"0001468748","company_name":"Kodiak Sciences Inc.","filed_at":"2026-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.136512+00:00","generated_at":"2026-05-15T08:08:44.526328+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Kodiak reports positive Phase 3 GLOW2 data for Zenkuda; plans accelerated BLA","bullets":["Zenkuda Phase 3 GLOW2: 62.5% vs 3.3% achieved ≥2-step DRSS improvement (p<0.0001).","85% risk reduction in sight-threatening complications (2.4% vs 15.8%, p=0.0001); no intraocular inflammation.","DAYBREAK Phase 3 wet AMD study fully enrolled (690 subjects); topline expected Sept 2026.","Q4 2025 net loss $56.7M ($1.04/shr); cash $209.9M; Dec 2025 equity raise net $173M.","KSI-101 Phase 3 PEAK topline 4Q2026, PINNACLE 2Q2027; Phase 1b APEX data showed robust responses."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-134854","json":"https://secwatch.observer/filing/0001193125-26-134854.json","markdown":"https://secwatch.observer/filing/0001193125-26-134854.md","text":"https://secwatch.observer/filing/0001193125-26-134854.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1468748/000119312526134854/0001193125-26-134854-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1468748/000119312526134854/kod-20260331.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:08:44.526328+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7ff12ef75319f3cd877c7336c178c4f5bed322fd","claim":"Kodiak Sciences Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income Net loss for the fourth quarter of 2025 was $56.7 million, or $1.04 per share on both a basic and diluted basis.","evidence_excerpt":"On March 31, 2026, Kodiak Sciences Inc. (the “Company”) published a press release reporting the Company’s financial results for the quarter and year ended December 31, 2025 and business highlights.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1468748/000119312526134854/0001193125-26-134854-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2025"},{"label":"Net income","value":"Net loss for the fourth quarter of 2025 was $56.7 million, or $1.04 per share on both a basic and diluted basis"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}